10-K
Annual Report
AGENUS INC
AGEN
NASDAQ
CIK: 1098972
File #: 000-29089
Balance Sheet
62 line items · 2 periods
XBRL
| Item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
ASSETS | ||
Cash and cash equivalents | 2,998,000 | 40,437,000 |
Cost | 417,000 | 6,954,000 |
Estimated Fair Value | 417,000 | 6,954,000 |
Institutional Money Market Funds - Cost | 417,000 | 6,954,000 |
Institutional Money Market Funds - Estimated Fair Value | 417,000 | 6,954,000 |
Accounts receivable | 1,831,000 | 407,000 |
Related party note receivable from MiNK Therapeutics, Inc. | 5,000,000 | — |
Related Parties | 5,179,000 | 0 |
Prepaid expenses | 785,000 | 2,315,000 |
Assets held for sale | 121,554,000 | 0 |
Other current assets | 1,089,000 | 2,415,000 |
Total current assets | 133,436,000 | 45,574,000 |
MiNK Therapeutics, Inc. | 13,848,000 | — |
Property, plant and equipment, net of accumulated amortization and depreciation of $47,468 and $72,553 at December 31, 2025 and 2024, respectively | 15,470,000 | 120,087,000 |
Operating lease right-of-use assets | 7,744,000 | 27,308,000 |
Goodwill | 24,092,000 | 24,092,000 |
Acquired intangible assets, net of accumulated amortization of $17,325 and $16,986 at December 31, 2025 and 2024, respectively | 3,037,000 | 3,376,000 |
Equity method investment in MiNK Therapeutics, Inc. | 24,277,000 | 0 |
MiNK Therapeutics, Inc. | 44,900,000 | — |
Agenus Inc. | 15,400,000 | — |
Related Parties | 15,435,000 | 0 |
Other long-term assets | 3,307,000 | 5,834,000 |
Total assets | 226,798,000 | 226,271,000 |
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT | ||
Current portion, long-term debt | 44,655,000 | 2,698,000 |
2015 Subordinated Notes | 10,353,000 | 2,471,000 |
Debentures | 146,000 | 146,000 |
Other Services | 104,000 | 81,000 |
Promissory Note | 24,052,000 | — |
Zydus Promissory Note | 10,000,000 | — |
Current portion, liability related to sale of future royalties and milestones | 109,323,000 | 111,978,000 |
Current portion, deferred revenue | 0 | 31,000 |
Current portion, operating lease liabilities | 1,034,000 | 2,446,000 |
Accounts payable | 82,987,000 | 61,470,000 |
Accrued liabilities | 34,223,000 | 34,961,000 |
Liabilities held for sale | 50,738,000 | — |
Other current liabilities | 529,000 | 7,817,000 |
Total current liabilities | 323,489,000 | 221,401,000 |
MiNK Therapeutics, Inc. | 13,031,000 | — |
Long-term debt, net of current portion | 0 | 30,473,000 |
2015 Subordinated Notes | — | 10,500,000 |
Promissory Note | — | 19,973,000 |
Liability related to sale of future royalties and milestones, net of current portion | 169,660,000 | 224,389,000 |
Deferred revenue, net of current portion | 1,143,000 | 1,143,000 |
Operating lease liabilities, net of current portion | 10,108,000 | 54,551,000 |
Other long-term liabilities | 259,000 | 738,000 |
STOCKHOLDERS' DEFICIT | ||
Series A-1 convertible preferred stock | 0 | 0 |
Common stock, par value $0.01 per share; 800,000,000 shares authorized at December 31, 2025 and 2024; 35,320,397 shares and 23,634,670 shares issued and outstanding at December 31, 2025 and 2024, respectively | 353,000 | 236,000 |
Additional paid-in capital | 1,911,740,000 | 1,857,662,000 |
Accumulated other comprehensive loss | (439,000) | (1,398,000) |
Accumulated deficit | (2,182,765,000) | (2,182,880,000) |
Total stockholders' deficit attributable to Agenus Inc. | (271,111,000) | (326,380,000) |
Non-controlling interest | (6,750,000) | 19,956,000 |
Total stockholders' deficit | (277,861,000) | (306,424,000) |
Non-controlling Interest | (6,750,000) | 19,956,000 |
Common Stock | 353,000 | 236,000 |
Additional Paid-in Capital | 1,911,740,000 | 1,857,662,000 |
Accumulated Deficit | (2,182,765,000) | (2,182,880,000) |
Accumulated Other Comprehensive Income (Loss) | (439,000) | (1,398,000) |
Total liabilities, convertible preferred stock and stockholders' deficit | 226,798,000 | 226,271,000 |